Construction of new community center in Snellville to start in May
The $11.3 million Community Center will be in T.W. Briscoe Park and is supposed to begin construction on May 5. City officials said the site will be about 34,000 square feet and have two basketball courts, an indoor walking track, outdoor pavilion, two multi-purpose activity rooms and one aerobics room.
The project will be near the current Snellville Parks and Recreation office, according to the city.
'This is a project that has been in the conceptual discussion phase for over 20 years,' Mayor Barbara Bender said. 'It's very exciting to get to this point. We look forward to the Community Center at T.W. Briscoe Park becoming a place where people can exercise, stay fit and healthy, relax, and gather together for decades to come.'
Goodwin Mills Cawood is the designer for the new facility, with construction handled by Place Services, Inc.
[DOWNLOAD: Free WSB-TV News app for alerts as news breaks]
The city said the buildout should be done by summer 2026.
'Briscoe Park offers our visitors over 95 acres of natural, passive areas and active recreation space for programming, all in one beautiful setting,' Lisa A. Platt, Director of Parks and Recreation, said. 'With the addition of the T.W. Briscoe Community Center, Snellville Parks and Recreation will be able to elevate our service and programming for the community and continue working toward our vision for innovative programming, to provide recreational opportunities that ensure quality of life for all in mind, body and spirit.'
TRENDING STORIES:
Real check, fake story: Georgia man accused of stealing $32 million in tax refunds
'You're up next:' Uber opens waitlist for autonomous rides with Waymo in Atlanta
Woman shot, killed at DeKalb County motel
Most of the funding for the project is sourced from a Special Purpose Local Option Sales Tax, approved by voters in 2023 for recreation projects, officials said.
Another portion of funding is from a separate SPLOST approved in 2017 as well as a $900,000 grant from Gwinnett County through a federal Community Development Block Grant program.
According to Snellville, visitors going to Briscoe Park should get ready for the following limited impacts:
East Park Drive will be closed in its entirety from Lenora Church Road to the four-way stop at Sawyer Parkway inside Briscoe Park
Outdoor basketball courts will be closed beginning May 5. The courts will be removed in order for the new Community Center to be built. Indoor courts will be available for play once the center is completed and new outdoor basketball courts are planned for future implementation of the Park Master Plan.
Parking for Staley Field will be in front of the Parks and Recreation Office or at the lots near the softball fields.
The fitness trail behind the park office will remain open initially, but will be re-routed at various times to accommodate multiple phases of the construction process.
The city will host a May 1 groundbreaking for the new community center on May 1 at 4:30 p.m.
[SIGN UP: WSB-TV Daily Headlines Newsletter]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
23 minutes ago
- Business Wire
AG Mortgage Investment Trust, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call
NEW YORK--(BUSINESS WIRE)--AG Mortgage Investment Trust, Inc. (NYSE: MITT) (the 'Company') announced today that it will release second quarter 2025 financial results prior to market open on Friday, August 1, 2025. The Company will host a conference call to discuss the results on Friday, August 1, 2025, at 8:30 a.m. Eastern Time. To participate in the call by telephone, please dial (800) 274-8461 at least five minutes prior to the start time. International callers should dial (203) 518-9814. The Conference ID is MITTQ225. To listen to the live webcast of the conference call, please go to and register using the same Conference ID. A presentation will accompany the conference call and will be available prior to the call on the Company's website, under 'Presentations' in the 'News & Presentations' section. For those unable to listen to the live call, an audio replay will be available on August 1, 2025 through 9:00 a.m. Eastern Time on September 1, 2025. To access the replay, please go to the Company's website at About AG Mortgage Investment Trust, Inc. AG Mortgage Investment Trust, Inc. is a residential mortgage REIT with a focus on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. AG Mortgage Investment Trust, Inc. is externally managed and advised by AG REIT Management, LLC, a subsidiary of Angelo, Gordon & Co., L.P., a diversified credit and real estate investing platform within TPG. Additional information can be found on the Company's website at About TPG Angelo Gordon Founded in 1988, Angelo, Gordon & Co., L.P. ('TPG Angelo Gordon') is a diversified credit and real estate investing platform within TPG. The platform currently manages approximately $92 billion across a broad range of credit and real estate strategies. For more information, visit
Business Wire
23 minutes ago
- Business Wire
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the 'Company' or 'Delcath'), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to three individuals whose employment commenced in June 2025. The grants resulted in the right to purchase 52,500 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan ('Plan'). The options were granted on June 30, 2025, the date the Compensation Committee approved the stock option included within the equity inducements and are subject to an exercise price equal to $13.60, the closing price of Delcath's common stock on June 30, 2025. One-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options vesting in equal monthly installments over the following twenty-four months. The options have a ten-year term, and the vesting of the options are subject to the employee's continued employment with Delcath on each vesting date. The above-described awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and granted pursuant to the terms of the Plan. About Delcath Systems, Inc. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.
Business Wire
23 minutes ago
- Business Wire
Rosen Law Firm Urges Luminar Technologies, Inc. (NASDAQ: LAZR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Luminar Technologies, Inc. (NASDAQ: LAZR) securities between March 20, 2025 and May 14, 2025, both dates inclusive (the 'Class Period'). Luminar purports to be a technology company that specializes in advanced 'Light Detection and Ranging' ('LiDAR') hardware and software solutions for vehicles. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Luminar Technologies, Inc. (NASDAQ: LAZR) Misled Investors Regarding its Business Operations. According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Austin Russell ('Russell'), Luminar's President, CEO and Chairman of the Board, was engaged in undisclosed conduct that would make him the subject of an inquiry by the Audit Committee of the Board of Directors; (2) this conduct created material risk that Russell would be released form his positions at Luminar; (3) Luminar's loss of Russell as an employee would then create material risk of adversely affecting Luminar's business by making it more difficult to compete with other market participants, manage R&D activities, and retain existing customers or cultivate new ones. Further, negative public perception and negative news related to Russell could adversely affect Luminar's brand relationships with customers, or standing in the industry; (4) accordingly, Luminar had no reasonable basis to provide and/or maintain Luminar's financial guidance; and (5) as a result, defendants' public statements were materially false and/or misleading at all times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Luminar Technologies, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 22, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
